TriSalus Life Sciences Inc (NAS:TLSI)

Q1 2025 TriSalus Life Sciences Inc Earnings Call Transcript

May 15, 2025 / 12:00 PM GMT

Release Date Price: $5.11 (+4.29%)

Transcript 10-Q8-K

Key Points

Positve

TriSalus Life Sciences Inc (TLSI) reported a 42% increase in net sales for Q1 2025 compared to Q1 2024, demonstrating strong revenue growth.
The company achieved significant milestones, including the completion of phase one trials for Nelatolamo, positioning it for potential pharmaceutical partnerships.
TLSI expanded its commercial footprint by increasing the number of unique ordering accounts by 39% compared to Q1 2024, adding 32 new accounts.
The Centers for Medicare and Medicaid Services issued a new reimbursement code for TriNav, doubling its reimbursable use and supporting broader adoption.
TLSI successfully raised approximately $22 million in gross proceeds through a private placement, strengthening its financial position for future investments.

Negative

Despite revenue growth, TLSI reported operating losses of $7.3 million for Q1 2025, although this was an improvement from the previous year.
The company's gross margin decreased slightly to 84% in Q1 2025 from 85% in Q1 2024 due to decreased factory volumes during clean room expansion.
TLSI does not anticipate being EBITDA positive or cash flow positive in 2025, as it continues to invest in strategic areas of the business.
The company faces challenges in scaling its sales force and ensuring new hires are effectively integrated to drive meaningful volume.
There is uncertainty regarding the final data and outcomes from the Nelatolamo trials, which could impact potential partnerships and future revenue.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TLSI.OQ - TriSalus Life Sciences Inc
Q1 2025 TriSalus Life Sciences Inc Earnings Call
May 15, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning and welcome to Trialis Life Science's first quarter 2025 earnings conference call. Currently all participants are on the listen-only mode. We will be facilitating a question and answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Alex Grossman, associate director with Lifesite Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator, and thank you all for participating in today's call. Joining me today from

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.